Holen Sie sich die Stockscreener-App
39.61
6.56%
-2.78
Vorhandelsmarkt:
38.50
-1.11
-2.80%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$42.39
Offen:
$41.99
24-Stunden-Volumen:
1.94M
Relative Volume:
0.83
Marktkapitalisierung:
$5.48B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-28.50
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
+0.33%
1M Leistung:
+9.66%
6M Leistung:
+174.69%
1J Leistung:
+103.23%
1-Tages-Spanne:
$39.28
$43.20
1-Wochen-Bereich:
$38.65
$43.69
52-Wochen-Spanne:
$9.57
$43.69
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Vergleichen Sie ARWR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
39.61 | 5.86B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Will Arrowhead Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
How to escape a deep drawdown in Arrowhead Pharmaceuticals Inc.Quarterly Earnings Report & Free Fast Entry Momentum Trade Alerts - newser.com
Hypertriglyceridemia: Clinical Landscape, Companies, Therapeutic Assessment, Treatment Algorithm, and Pipeline Insights | Key Players: NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer B - Barchart.com
Trend analysis for Arrowhead Pharmaceuticals Inc. this week2025 Market Trends & Detailed Earnings Play Strategies - newser.com
How sentiment analysis helps forecast Arrowhead Pharmaceuticals Inc.July 2025 Review & High Conviction Investment Ideas - newser.com
Risk vs reward if holding onto Arrowhead Pharmaceuticals Inc.Market Performance Summary & Advanced Technical Analysis Signals - newser.com
Is Arrowhead Pharmaceuticals Inc. stock cheap at current valuationMarket Sentiment Report & Technical Pattern Alert System - newser.com
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockJuly 2025 Macro Moves & High Return Trade Opportunity Guides - newser.com
Why Arrowhead Pharmaceuticals Inc. is moving todayJuly 2025 Decliners & Fast Entry Momentum Alerts - newser.com
What makes Arrowhead Pharmaceuticals Inc. (HDP1) stock appealing to growth investors2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
Can Arrowhead Pharmaceuticals Inc. stock sustain revenue growthDividend Hike & Consistent Income Trade Ideas - newser.com
Will Arrowhead Pharmaceuticals Inc. stock continue dividend increasesBond Market & AI Driven Stock Movement Reports - newser.com
Will Arrowhead Pharmaceuticals Inc. stock split again soonMarket Risk Analysis & Safe Entry Zone Tips - newser.com
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock signals breakout potential2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Pinnacle Associates Ltd. Purchases 70,399 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com
How Arrowhead Pharmaceuticals Inc. (HDP1) stock behaves under inflation pressureEarnings Beat & High Accuracy Swing Entry Alerts - newser.com
How to build a dashboard for Arrowhead Pharmaceuticals Inc. stockJuly 2025 Action & Long-Term Growth Stock Strategies - newser.com
Targeted Drug Delivery Market Set to Witness Massive Growth - openPR.com
Is Arrowhead Pharmaceuticals Inc. showing signs of accumulation2025 Price Momentum & Risk Managed Trade Strategies - newser.com
Why analysts remain bullish on Arrowhead Pharmaceuticals Inc. stockWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
Can Arrowhead Pharmaceuticals Inc. stock hit analyst price targets2025 Pullback Review & Expert Curated Trade Ideas - newser.com
Is Arrowhead Pharmaceuticals Inc. stock attractive for growth ETFsJuly 2025 Breakouts & High Yield Equity Trading Tips - newser.com
Best data tools to analyze Arrowhead Pharmaceuticals Inc. stockQuarterly Performance Summary & Accurate Trade Setup Notifications - newser.com
Can Arrowhead Pharmaceuticals Inc. stock reach $100 price targetEarnings Overview Report & Daily Technical Stock Forecast Reports - newser.com
Combining price and volume data for Arrowhead Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - newser.com
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Severe Hypertriglyceridemia - MSN
Arrowhead Pharmaceuticals Advances in FSHD1 Treatment with ARO-DUX4 Study - MSN
How buybacks impact Arrowhead Pharmaceuticals Inc. stock value2025 Trading Recap & Intraday High Probability Setup Alerts - newser.com
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):